# Research Peptide Fundamentals research peptides, documented end to end > Research Peptide Fundamentals Research Peptides — Radiant Peptide Supply — Research Peptide Fundamentals research peptides explained through the documentation chain: specifications, certificates, custody, independent assays, evidence, and safety context. **DOCUMENTATION BRIEF / 01** Four compounds. Four evidence profiles. One clinical reading frame for specifications, certificates, custody records, independent assays, and the claims those documents can—and cannot—support. ### [GHK-Cu](/ghk-cu) ![GHK-Cu research illustration](images/ghk-cu.webp) A copper-binding tripeptide with topical, ex vivo, and mechanistic evidence. The key documentation issue is form: free GHK and copper-bound GHK-Cu are not interchangeable. ### [Tesamorelin](/tesamorelin) ![Tesamorelin research illustration](images/tesamorelin.webp) A prescription GHRH analogue with a defined approved use and randomized human evidence. Identity, custody, and product status determine whether that evidence is relevant. ### [KPV](/kpv) ![KPV research illustration](images/kpv.webp) A melanocortin-derived tripeptide studied mainly in cells and animal colitis models. Its file is mechanism-rich but lacks human clinical validation. ### [Retatrutide](/retatrutide) ![Retatrutide research illustration](images/retatrutide.webp) An investigational triple-receptor agonist with striking Phase 2 results and unresolved long-term questions. Trial material is not evidence for an unverified vial. ## The short version A peptide label is a claim. A usable research record is a chain of evidence. It begins with a written specification—what the material is supposed to be—and continues through a certificate tied to a batch, records showing who handled it, and assays that independently test identity and quality. Each link answers a different question. None answers every question. Radiant Peptide Supply is an independent editorial digest, not a seller. It uses that documentation chain to organize four very different compounds: GHK-Cu, tesamorelin, KPV, and retatrutide. The pages separate chemical identity from biological findings, preclinical work from human trials, and regulated products from investigational material. The aim is practical: establish what a document actually demonstrates before relying on the claim attached to it. The same discipline applies to literature. A result belongs to the compound, formulation, model, population, and conditions that were studied. It does not automatically transfer to material from another source or to a different use. That boundary is the central finding of this briefing. ## The documentation chain The chain has four working parts. **Specifications** set acceptance criteria before testing begins. They should identify the compound, expected form, and quality attributes relevant to the intended laboratory method. **Certificates** report results for a stated lot, but their value depends on traceability, methods, dates, and whether the issuing laboratory is independent of the seller. A generic sheet without a lot connection is not a batch record. **Custody records** connect the tested sample to the material under discussion. They document transfers, storage, seals, and sample handling. Without that connection, even a technically sound assay may describe a different sample. **Independent assays** then test defined questions. Identity, purity, water content, residual solvents, sterility, and endotoxin are separate questions that require appropriate methods; a single chromatogram is not a universal quality certificate. The literature reinforces this specificity. GHK-Cu studies distinguish a copper complex from free peptide and show that skin delivery is a material constraint [1][5]. Tesamorelin evidence concerns a characterized GHRH analogue used in controlled clinical settings [8][10]. KPV findings are still chiefly cell and mouse findings [13][14][15][16]. Retatrutide results come from regulated clinical-trial material, while the compound remains investigational [18][20][21][22]. Documentation does not create efficacy. It establishes whether the material being discussed is even positioned to be compared with the literature. ## What are research peptides? Peptides are short chains of amino acids. They can serve as signals, fragments of larger proteins, or engineered receptor agonists. That broad definition hides major differences. GHK-Cu is a small copper-binding complex associated with tissue-remodeling research. KPV is a three-amino-acid fragment derived from alpha-melanocyte-stimulating hormone [17]. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. Retatrutide is an engineered molecule designed to activate three metabolic receptors [19]. The phrase **research peptide** does not establish legal status, quality, or suitability for human use. Tesamorelin has an FDA-approved prescription indication for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [9]. Retatrutide remains investigational. KPV has no human clinical-trial evidence in this corpus. GHK-Cu has a topical cosmetic record, while systemic routes lack validated human evidence. These are distinct regulatory and evidence categories, not minor footnotes. A disciplined reading therefore asks: What exact form was studied? Was the work conducted in cells, animals, ex vivo tissue, or people? Was the endpoint mechanistic, cosmetic, metabolic, or clinical? Was the tested material controlled by a trial protocol? The [comparison brief](/compare) applies those questions across all four files. ## How to read this desk Each compound page follows the same order: identity, mechanism, findings, reported experience, cautions, and unresolved questions. Numbered citations lead to the shared [reference register](/references). Quantitative results remain attached to the cited study rather than being converted into promises. Community accounts appear only when the corpus contains them, and they are labeled **anecdotal, not clinical evidence**. Absence of anecdote is not evidence of absence; it means the composed source did not include a reliable signal set for that compound. The most important check is consistency across the chain. A specification may name the correct sequence while omitting the form used in the literature. A certificate may list purity while leaving identity uncertain. An independent result may be technically credible yet disconnected from the lot by weak custody records. A clinical publication may be rigorous but irrelevant to an unverified sample. Read the pages as a sequence of bounded questions, not as endorsements. --- An independent clinical-style digest tracing peptide claims from specification to assay to literature—not a vendor, laboratory certificate, or source of medical advice.